Listed

Tempest Therapeutics, Inc.: Form 10-K for the period ended Dec 31, 2012

Filed with the SEC on Feb 25, 2013 and accepted by EDGAR at Feb 25, 2013, 08:34 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2012-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development12 months2012-01-01 to 2012-12-31$6.3mus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2012-01-01 to 2012-12-31−$13.5mus-gaap:OperatingIncomeLoss
Net income12 months2012-01-01 to 2012-12-31−$13.5mus-gaap:NetIncomeLoss
Diluted EPS12 months2012-01-01 to 2012-12-31−$2.33us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow12 months2012-01-01 to 2012-12-31−$11.2mus-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Capital expenditure12 months2012-01-01 to 2012-12-31$849.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2012-12-31$14.8mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2012-12-31$32.0mus-gaap:AssetsCurrent
Total assetsAt period end2012-12-31$32.8mus-gaap:Assets
Current liabilitiesAt period end2012-12-31$2.1mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2012-12-31$2.1mus-gaap:Liabilities
Shareholders' equityAt period end2012-12-31$30.7mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001047469-13-001570. Last ingested by Listed: Nov 15, 2026, 00:20 ET. Listed shows no prices and gives no investment advice.